Revenio Group’s iCare and EyeCheq announce strategic partnership and minority investment

iCare, part of the Revenio Group, and the U.S.-based eye health innovation company EyeCheq, have entered into a partnership agreement and strategic minority investment to expand access to point-of-care eye screening through the deployment of EyeCheq stations in the United States. The partnership aims to accelerate the adoption and accessibility of automated screening solutions and the development of AI-based diagnostics.

EyeCheq stations are designed for busy and easily accessible environments, such as labs and pharmacies located in retail stores, occupational health clinics, and primary healthcare facilities. The stations integrate the iCare DRSplus fundus imaging device in addition to other ophthalmic devices. Imaging results are reviewed by Eyecheq’s network of licensed eye care physicians, including optometrists and ophthalmologists. The stations are available in multiple languages to ensure accessibility for diverse populations. Screened individuals receive a personalized report within 24 hours, enabling fast and high-quality screening for diabetic retinopathy, glaucoma, age-related macular degeneration, and other vision-related needs.

In connection with the investment, EyeCheq announced the appointment of John Floyd, VP of U.S. Sales, to its Board of Directors — further aligning the two organizations at the governance level as they accelerate joint commercial and clinical initiatives.

“We want to be a pioneer in creating eye-health solutions that combine top-level technology, artificial intelligence, and patient-centered care. We are already conducting pilot deployments of EyeCheq stations in the United States with several key partners. The partnership strengthens the position of iCare and our devices in the U.S. vision screening and eye care market. EyeCheq stations are a highly scalable concept that brings screening into non-traditional environments closer to people’s everyday lives – places where they already go. With our innovative solutions, we improve the quality of clinical diagnostics and streamline patient care pathways in a cost-effective way, while conserving society’s limited professional resources”, says Revenio CEO Jouni Toijala.

“Our partnership with iCare represents a shared commitment to transforming access to eye care,” said Dr. Rashid Taher, CEO of EyeCheq. “Together, we’re removing traditional barriers to screening by putting cutting-edge diagnostic technology directly into easily accessible settings for communities that need it most. We are seeing the automation of the iCare imaging devices as a key part of the successful adoption of our platform in primary care and retail settings, which have tremendous potential to scale.”

More than 530 million people live globally with diabetes, over a third of whom are at risk of vision-threatening diabetic retinopathy*. Glaucoma, age-related macular degeneration, and uncorrected refractive errors contribute significantly to global visual impairment. The joint solution by EyeCheq and iCare brings high-quality screening closer to those who need it — making sight-saving screening more accessible than ever.

*Source: International Diabetes Federation (IDF) Diabetes Atlas, 10th Edition (2021) URL: https://diabetesatlas.org/

For further information
CEO Jouni Toijala
+358 50 484 0085
jouni.toijala@revenio.fi

Ali Khoshnevis
Co-Founder, CSO EyeCheq
ali@eyecheq.com

Distribution
Main media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a leading turnkey solutions provider in the global eye care market. The group offers fast, user-friendly, and reliable tools for diagnosing a wide variety of eye diseases. Revenio’s solutions include e.g. tonometers, fundus imaging devices, optical coherence tomography (OCT), perimeters, multimodal devices, refraction systems, and software solutions under iCare and Visionix.

In May 2026, Revenio joined forces with Visionix, creating the most innovative, creative and comprehensive entity serving eye care professionals across optometry, optical retail and ophthalmology. In 2025, the Group’s net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

https://icare-world.com/us/product/screening/

About EyeCheq
EyeCheq is a digital health company revolutionizing vision screening through its tech-enabled telehealth platform. Designed for scalability and simplicity, EyeCheq enables rapid, non-invasive eye screenings at the point of care - helping to detect sight-threatening conditions early. EyeCheq partners with healthcare systems, labs, employers, and retail health companies to close gaps in eye care access and drive better outcomes for millions of patients. https://www.eyecheq.com/